¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Deficiency of other specified B group vitamins"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • linkage group
    ¿¬°ü±º
  • low risk group
    ÀúÀ§Ç豺
  • methyl group
    ¸ÞÆ¿±â
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥)
  • prosthetic group
    1. º¸°áºÐÀÚ´Ü 2. º¸°á¿øÀÚ´Ü
  • Rh blood group system
    RhÇ÷¾×Çüü°è
  • soluble group
    °¡¿ëÇØ±º
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • diagnosis related group
    À¯»çÁø´Ü±ºÀÇ·áºñÁöºÒ¹ý
  • didactic group therapy
    ±³À°Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • end group
    ¸»´Ü±â
  • end group spine
    ±ê³¡°¡½Ã
  • enteric group
    âÀÚ±Õ±º
  • evocative group therapy
    Ç¥ÇöÁý´Ü¿ä¹ý
  • functional group
    ÀÛ¿ë±â
  • group
    ¹«¸®, ±º, Áý´Ü
  • group-specific
    ±ºÆ¯ÀÌ-
  • glucophore group
    ´ã´ç±â
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin A deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ(Áõ)
  • immunologic deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunologic deficiency syndrome
    ¸é¿ª°áÇÌ ÁõÈıº(¡­ÌÀù¹ ñøý¦ÏØ)
  • immunological deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • inosine phosphorylase deficiency
    À̳ë½ÅÆ÷½ºÆ÷¸±¶óÁ¦°áÇÌ(Áõ)
  • phosphate dehydrogenase deficiency
    Àλ꿰ݼö¼ÒÈ¿¼Ò°áÇÌÁõ
  • pituitary deficiency
    ÇϼöüºÎÀü(¡­ÝÕîï).
  • pituitary deficiency
    üºÎÀü(ù»á÷ô÷ÝÕîï)
  • pituitary hormone deficiency (pituitary dwarfism)
    ³úÇϼöüȣ¸£¸ó°áÇÌ (³úÇϼöü³­
  • protein-calorie deficiency
    ´Ü¹é(Áú)¿­·®°áÇÌ(Ó±ÛÜ(òõ)æðÕáÌÀù¹)
  • pyridoxine deficiency
    ÇǸ®µ¶½Å°áÇÌ(Áõ)(¡­ÌÀù¹(ñø))
  • reaction deficiency
    ¹ÝÀÀ°áÇÌ
  • ABO blood group
    ABO Ç÷¾×Çü.
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group II fiber
    Á¦¥±¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
HIVD Herniation(Herniated) of Inter-Vertebral Disc
  - Cervical HIVD
   &...
PEEP Positive End-Expiratory Pressure
  ? Ix
    1. PaO2 < 60 mmHg, ...
AL absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru...
AMSAODD American Medical Society on Alcoholism and Other Drug Dependencies
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
Group 4 group
Group A group 1
group B group A
Group D group
Group I group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • factor VIII deficiency
    Á¦ 8ÀÎÀÚ °áÇÌ
  • factor XI deficiency
    Á¦11ÀÎÀÚ °áÇÌ
    ÀÌ ÀÎÀÚ°¡ ºÎÁ·µÇ¸é Ç÷¿ìº´ C³ª Rosenthal ÁõÈıºÀ¸·Î ºÒ¸®´Â Àü½Å¼º Ç÷¾× ÀÀ°í Àå¾Ö¸¦ ÀÏÀ¸Å°´Âµ¥ °íÀüÀû Ç÷¿ìº´°ú À¯»çÇÏ´Ù.
  • folate deficiency anemia
    ¿±»ê °áÇ̼º ºóÇ÷
  • folic acid deficiency anemia
    ¿±»ê °áÆð¼º ºóÇ÷
  • fructokinase deficiency
    ÇÁÁ¦ °áÇÌ
  • hexokinase deficiency
    Çí¼ÒŰ³ªÁ¦ °áÇÌ
  • immune deficiency disease
    ¸é¿ª °áÇÌ Áúȯ, ¸é¿ª °áÇ̺´
    ¸é¿ª °èÅëÀ» ±¸¼ºÇÏ´Â ¿ä¼ÒÀÇ ±â´É Àå¾Ö¿¡ ÀÇÇÏ¿© ÃÊ·¡µÇ´Â Áúȯ ±º.
  • immunity deficiency
    ¸é¿ª °áÇÌ
    µ¿ÀǾî=immunodeficiency.
  • immunological deficiency state
    ¸é¿ª °áÇÌ »óÅÂ
  • iron deficiency anemia
    ö °áÇ̼º ºóÇ÷
    1. Àú»ö¼Ò¼º, ¼Ò±¸¼º ÀûÇ÷±¸¼º ºóÇ÷ÀÇ ´ëÇ¥Àû Áúȯ. öÀÇ °áÇÌ¿¡ ÀÇÇÏ¿© Ç÷»ö¼ÒÀÇ »ý¼ºÀÌ ÃæºÐÈ÷ ÇàÇÏ¿©ÁöÁö ¾Ê±â ¶§¹®¿¡ ÀûÇ÷±¸ ¼öº¸´Ùµµ Ç÷»ö¼Ò ³óµµ°¡ ÇöÀúÇÏ°Ô °¨¼ÒÇÑ´Ù. 2. ö ÀúÀå·®ÀÇ ÀúÇÏ, °áÇÌ, Ç÷û ö ³óµµÀÇ ÀúÇÏ, transferrin¾ç »ó½Â, transferrin Æ÷È­µµÀÇ ÀúÇÏ, Àú»ö¼Ò¼º ´ëÀûÇ÷±¸¸¦ Ư¡À¸·Î ÇÏ´Â ºóÇ÷.
  • isolated T-cell deficiency
    T ¼¼Æ÷ °áÇÌ
  • lactase deficiency
    ¶ôŸÁ¦ °áÇÌ
  • mental deficiency
    Áö´É ¹Ú¾à, Áö´É ¹Ú¾àÁõ, Á¤½Å ¹Ú¾àÁõ
    ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇØ¼­ Áö´É ¹ß´ÞÀÌ Æò±Õº¸´Ù ³·°í Á¤½ÅÀû, ½ÅüÀû Àå¾Ö·Î ÀÎÇØ »çȸ »ýȰ¿¡ ´ëÇÑ ÀûÀÀÀÌ °ï¶õÇÑ »óÅÂ. Á¤½Å Áöü¶ó°íµµ ÇÑ´Ù. Çö´ë ÀÇÇп¡¼­´Â ÁøÇ༺ ¸¶ºñ¿¡ ÀÇÇÑ Ä¡¸Å³ª ÀϽÃÀûÀÎ Á¤½Å ±â´ÉÀÇ ÅðÇà°ú ±¸º°ÇÏ¿© Ç×±¸ÀûÀÎ Áöü »óŸ¦ ÀǹÌÇÑ´Ù. ¶ÇÇÑ ÀÏ¹Ý Áö´ÉÀÇ °áÇÔ¸¸ÀÌ ¾Æ´Ï¶ó '»çȸ »ýȰ¿¡¼­ÀÇ ½ÇõÀû Áö´É'À̶ó ºÎ¸¦ ¸¸ÇÑ Ãø¸é¿¡µµ ÁÖ¸ñÇÏ°Ô µÇ¸é¼­ Á¤½Å ¹Ú¾àÀÇ ºÐ·ù´Â »çȸÀÇ ÀûÀÀµµ¿Í »çȸÀû »ýȰ ´É·Â Á¤µµ¸¦ ¹èÇÕ½ÃŰ°Ô µÇ¾ú´Ù.
  • mineral deficiency
    ¹«±âÁú °áÇÌ, ¹«±âÁú °áÇÌÁõ
  • myeloperoxidase deficiency
    ¸¶ÀÌ¿¤·Î ÆÛ·Ï½Ãµ¥À̽º °áÇÌÁõ
    »ó¿°»öü¼º ¿­¼º ÇüÁú·Î À¯ÀüµÇ¸ç, Áß¼º±¸¿Í ´Ü±¸ÀÇ È£¾ÆÁÖ¸£¼º °ú¸³ ³»¿¡ MPO°¡ ÀüÇô ¾ø´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
placental sulfatase deficiency <enzyme> An enzyme defect in the placenta which results in failure of conversion of 16a-hydroxydehydroepiandrosterone to estriol; women with this condition rarely enter into spontaneous labour.
(05 Mar 2000)
platelet storage pool deficiency A group of disorders characterised by a decrease or lack of platelet dense bodies in which the releasable pool of adenine nucleotides and 5ht are normally stored.
(12 Dec 1998)
congenital antithrombin III deficiency Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait.
Inheritance: autosomal dominant.
(27 Sep 1997)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
congenital protein C or s deficiency This inherited disorder of blood coagulation is characterised by a deficiency of vitamin K dependent plasma proteins (C and s) that are naturally occurring anticoagulants. This disorder results in an increased risk of blood clot formation within the circulatory system.
(27 Sep 1997)
multiple glandular deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple sulfatase deficiency An inherited disorder (autosomal recessive) in which there is a failure to hydrolyze sulfatides and sulfated mucopolysaccharides; this failure leads to their accumulation in neural and extraneural tissues causing demyelination, sulfatiduria, facial and skeletal dysmorphism, etc.
(05 Mar 2000)
muscle phosphorylase deficiency Type V glycogen storage disease, affecting muscle, caused by deficiency of muscle phosphorylase.
(05 Mar 2000)
corpus luteum deficiency syndrome <syndrome> Functional disturbances caused by insufficient ovarian luteinization; reflected by inadequate luteal phase endometrial response.
(05 Mar 2000)
polyendocrine deficiency syndrome <syndrome> Polyglandular deficiency syndrome, associated pathologic dysfunction of several endocrine glands, as in Schmidt's syndrome.
(05 Mar 2000)
myophosphorylase deficiency glycogenosis Glycogenosis due to muscle glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in muscle.
Synonym: McArdle's disease, McArdle's syndrome, McArdle-Schmid-Pearson disease, myophosphorylase deficiency glycogenosis.
(05 Mar 2000)
potassium deficiency A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhoea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing polyuria and decreased maximal urinary concentrating ability with secondary polydipsia. (merck manual, 16th ed)
(12 Dec 1998)
hageman factor deficiency A deficiency of a specific blood clotting factor (XII) that may be genetic or acquired. Administration of heparin or severe liver disease may result in factor XII (Hageman factor) deficiency. There are usually no symptoms associated with this deficiency, but there may be symptoms of mild blood loss in some cases. Treatment is generally unnecessary. Individuals should be cautioned against the use of medications (for example aspirin, warfarin, heparin) with anticoagulant activity, due to risk of exaggerated effects.
(27 Sep 1997)
hepatophosphorylase deficiency glycogenosis Glycogenosis due to hepatic glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in liver and leukocytes.
Synonym: hepatophosphorylase deficiency glycogenosis, Hers' disease.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á